Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Week in Review: BeiGene Options DualityBio ADC in $1.3 Billion Agreement

publication date: Jul 15, 2023

Deals and Financings

  • Beijing’s BeiGene optioned global rights to a next-gen ADC candidate targeting solid tumor cancers from DualityBio of Shanghai in a $1.3 billion agreement;
  • WuXi Biologics, a global biologic drug CRDMO, will spin-off its biologics/small molecule bioconjugates subsidiary and conduct a $500 million Hong Kong IPO of the business;
  • Guangdong Sinotau Pharmaceuticals raised $152 million in its sixth funding to support its portfolio of novel diagnostic and therapeutic radiopharmaceuticals;
  • Zhejiang Doer Biologics of Hangzhou out-licensed global rights for one of its portfolio candidates to Germany’s BioNTech, the mRNA COVID vaccine company;
  • Suzhou GeneQuantum Healthcare expanded its collaboration with Aimed Bio, a South Korean biotech, adding five ADC candidates for unmet needs to the partnership;
  • Biosyngen, a cell and gene therapy company, established the Guangzhou-Singapore Technology Innovation and Translational Medicine Center to develop innovative cancer drug candidates;
  • Beijing InnoCare will collaborate with ArriVent, a Philadelphia area biopharma, to test a combination drug regimen for advanced non-small cell lung cancer;

Trials and Approvals

  • Shanghai Fosun Pharma reported its NDA filing for tenapanor, a therapy that lowers blood serum phosphorus in dialysis patients, was accepted for review in China;
  • Connect Biopharma, a Taicang-San Diego inflammatory disease company, presented four posters describing the progress of rademikibart, the company’s lead drug, in atopic dermatitis patients;
  • 280Bio, a US subsidiary of Shanghai Yingli Pharma, was approved to start US trials of a small molecule inhibitor of RAS signaling for tumors that are KRAS-resistant.

    Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here